Market News & Trends
Lipocine Makes Reverse Merger Move & Secures $38 Million to Advance Portfolio
Lipocine, Inc. recently announced it has entered into securities purchase agreement with gross proceeds of $38 million for the issuance and sale of approximately 6.3…
Rexahn In-Licenses Breakthrough Delivery Platform
Rexahn Pharmaceuticals, Inc. recently announced it has signed an exclusive license agreement with the University of Maryland, Baltimore (UMB) for a novel drug delivery platform,…
Telegraph Hill Partners Raises $310 Million for Life Science Companies
Telegraph Hill Partners (THP), a leading venture capital and growth equity firm dedicated exclusively to life science and healthcare investing, has had its final closing…
PolyTherics & Antitope Combine to Enable the Development of Better Biopharmaceuticals
PolyTherics Limited recently announced that it has merged with Antitope Limited to create an enlarged group with an extensive suite of services and technologies to…
Foamix Unveils Cutting-Edge Technology Platform for Enhanced Delivery
Foamix Ltd. recently announced the development of a new breakthrough platform technology for targeted drug delivery that can enhance the delivery of drugs to skin…
Spectrum Pharmaceuticals Acquires Talon Therapeutics
Talon Therapeutics, Inc. recently announced that a subsidiary of Spectrum Pharmaceuticals, Inc. entered into an agreement to purchase approximately 89% of the outstanding shares of…
NIH Scientists Find That Proteins Involved in Immunity Potentially Cause Cancer
A set of proteins involved in the body’s natural defenses produces a large number of mutations in human DNA, according to a study led by…
ThermoGenesis & TotipotentRx Form $18.6-Million Agreement
ThermoGenesis Corp. and TotipotentRx Corporation recently announced they have entered into a definitive merger agreement. The combined company is expected to become one of the…
Newly Found CLAMP Protein Regulates Genes
A newly discovered protein, found in many species, turns out to be the missing link that allows a key regulatory complex to find and operate…
Will Payments to Scientists for New Drugs Improve GSK's R&D Productivity?
By: John LaMattina, Forbes Contributor It’s pretty hard for a former pharma R&D scientist to ignore the following article from The Sunday Times, Banker Bonuses…
Auxilium & Swedish Orphan Biovitrum AB Enter $40-Million Collaboration
Auxilium Pharmaceuticals, Inc. and Swedish Orphan Biovitrum (Sobi) AB recently announced they have entered into a long-term collaboration for the development, supply, and commercialization of…
Ipsen to Buy Syntaxin for $207 Million
Syntaxin recently announced it has been acquired by Ipsen, with which it has two major strategic alliances. Under the terms of the agreement, Ipsen will…
Surefire Medical’s Infusion System Found Safe & Effective for Liver Cancer
Case reports published in the Journal of Cardiovascular and Interventional Radiology found that by using the Surefire Infusion System, radioembolization could be successfully performed without…
Inovio’s Delivery Technology Powers Durable, Best-in-Class T-Cell Responses From HIV Vaccine
Inovio Pharmaceuticals, Inc. recently announced the peer-reviewed publication of results from two Phase I trials (HVTN 070 and HVTN 080) of its PENNVAX-B preventive HIV…
Purolite & Codexis Announce Development & Marketing Collaboration
Purolite Corporation and Codexis, Inc. recently announced a joint collaboration to develop and market immobilized enzymes for the pharmaceutical industry. Enzymes are immobilized through binding…
Patients & Physicians Express Desire to Switch to Transdermal Drug Delivery
The $82-billion US drug delivery market is showing no signs of saturation, with major patent expiries, generic competition, tightening FDA regulations, and emerging drug delivery…
Ocera Therapeutics Announces Merger Completion
Ocera Therapeutics, Inc. and Tranzyme, Inc. recently announced that following a special meeting of the shareholders of Tranzyme held on July 15, 2013, the Ocera…
Immunocore & GSK in Potential $500-Million Plus Deal
Immunocore Limited, the Oxford-based biotechnology company developing novel biological drugs called ImmTACs to treat cancer and viral disease, recently announced it has entered into a…
Catalent & Biota Expand Alliance
Catalent Pharma Solutions recently announced it has entered into a contract with Biota Pharmaceuticals, Inc. to develop and provide filling and packaging capabilities to supply…
VIVUS, Inc. Strikes $121-Million Drug Deal
VIVUS, Inc. recently announced it has entered into a license and commercialization agreement and a supply agreement with Menarini and its wholly owned subsidiary BERLIN-CHEMIE…
